Express News | The top category for the most disruptive products, Saxagliptin oral immediate-release formulation, ranked 33 to 9, with Huisheng Biotech proposed as the primary candidate for the bid.

BreakingsDec 12 16:36

Express News | The latest bid price for Sitagliptin tablets in collective procurement has dropped to below 0.2 yuan per tablet, a decline of over 90%.

BreakingsDec 12 14:19

Zhejiang medicine (600216): The high prosperity in the vitamins industry is expected to continue, while innovative drugs are poised for development.

The company's dual core businesses of nutritional products and pharmaceutical manufacturing drive development simultaneously. The life nutritional products and pharmaceutical manufacturing sectors are the two major pillars of the company's business, establishing a series of products that include fat-soluble vitamins, vitamin-like substances, quinolone antibiotics, and anti-resistant antibiotics.

china great wallDec 9 00:00

Zhejiang medicine (600216.SH): Folate is not included among the main products.

On November 22, Gelonghui reported that zhejiang medicine (600216.SH) stated on the investor interaction platform that folic acid is not included in the company's main products.

Gelonghui FinanceNov 22 16:25

Express News | Zhejiang medicine: announced the "Quality improvement and efficiency enhancement, return on investment" action plan.

BreakingsNov 20 15:35

Express News | Summary of shareholding by listed companies on November 11th (table)

BreakingsNov 11 22:20